S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
Log in
TSE:AKU

Akumin Competitors

C$4.67
0.00 (0.00 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
C$4.62
Now: C$4.67
C$4.70
50-Day Range
C$3.72
MA: C$4.11
C$4.70
52-Week Range
C$1.75
Now: C$4.67
C$4.98
Volume11,400 shs
Average Volume61,718 shs
Market CapitalizationC$326.16 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Akumin (TSE:AKU) Vs. LXG, SQD, SVA, GEN, LMD, and VPT

Should you be buying AKU stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to Akumin, including LexaGene (LXG), SQI Diagnostics Inc. (SQD.V) (SQD), Sernova Corp. (SVA.V) (SVA), GeneNews (GEN), LED Medical Diagnostics (LMD), and VentriPoint Diagnostics Ltd. (VPT.V) (VPT).

LexaGene (CVE:LXG) and Akumin (TSE:AKU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.

Valuation & Earnings

This table compares LexaGene and Akumin's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LexaGeneN/AN/AN/AC($0.10)-11.58
AkuminC$269.04 million1.21C$-1,396,820.00C($0.02)-233.50

LexaGene has higher earnings, but lower revenue than Akumin. Akumin is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for LexaGene and Akumin, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LexaGene0000N/A
Akumin01102.50

Akumin has a consensus target price of C$4.25, indicating a potential downside of 8.99%. Given Akumin's higher possible upside, analysts plainly believe Akumin is more favorable than LexaGene.

Profitability

This table compares LexaGene and Akumin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LexaGeneN/AN/AN/A
AkuminN/AN/AN/A

Summary

Akumin beats LexaGene on 4 of the 5 factors compared between the two stocks.

SQI Diagnostics Inc. (SQD.V) (CVE:SQD) and Akumin (TSE:AKU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.

Valuation & Earnings

This table compares SQI Diagnostics Inc. (SQD.V) and Akumin's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQI Diagnostics Inc. (SQD.V)C$1.02 million125.51C$-10,402,144.00C($0.03)-12.34
AkuminC$269.04 million1.21C$-1,396,820.00C($0.02)-233.50

Akumin has higher revenue and earnings than SQI Diagnostics Inc. (SQD.V). Akumin is trading at a lower price-to-earnings ratio than SQI Diagnostics Inc. (SQD.V), indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for SQI Diagnostics Inc. (SQD.V) and Akumin, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SQI Diagnostics Inc. (SQD.V)0000N/A
Akumin01102.50

Akumin has a consensus target price of C$4.25, indicating a potential downside of 8.99%. Given Akumin's higher possible upside, analysts plainly believe Akumin is more favorable than SQI Diagnostics Inc. (SQD.V).

Profitability

This table compares SQI Diagnostics Inc. (SQD.V) and Akumin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SQI Diagnostics Inc. (SQD.V)N/AN/AN/A
AkuminN/AN/AN/A

Summary

Akumin beats SQI Diagnostics Inc. (SQD.V) on 5 of the 7 factors compared between the two stocks.

Sernova Corp. (SVA.V) (CVE:SVA) and Akumin (TSE:AKU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.

Valuation & Earnings

This table compares Sernova Corp. (SVA.V) and Akumin's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sernova Corp. (SVA.V)N/AN/AN/AC($0.03)-52.96
AkuminC$269.04 million1.21C$-1,396,820.00C($0.02)-233.50

Sernova Corp. (SVA.V) has higher earnings, but lower revenue than Akumin. Akumin is trading at a lower price-to-earnings ratio than Sernova Corp. (SVA.V), indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Sernova Corp. (SVA.V) and Akumin, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sernova Corp. (SVA.V)0000N/A
Akumin01102.50

Akumin has a consensus target price of C$4.25, indicating a potential downside of 8.99%. Given Akumin's higher possible upside, analysts plainly believe Akumin is more favorable than Sernova Corp. (SVA.V).

Profitability

This table compares Sernova Corp. (SVA.V) and Akumin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sernova Corp. (SVA.V)N/AN/AN/A
AkuminN/AN/AN/A

Summary

Akumin beats Sernova Corp. (SVA.V) on 4 of the 5 factors compared between the two stocks.

GeneNews (TSE:GEN) and Akumin (TSE:AKU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.

Valuation & Earnings

This table compares GeneNews and Akumin's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GeneNewsC$234,592.000.00C$-11,557,484.00C($0.07)N/A
AkuminC$269.04 million1.21C$-1,396,820.00C($0.02)-233.50

Akumin has higher revenue and earnings than GeneNews. Akumin is trading at a lower price-to-earnings ratio than GeneNews, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for GeneNews and Akumin, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GeneNews0000N/A
Akumin01102.50

Akumin has a consensus target price of C$4.25, indicating a potential downside of 8.99%.

Profitability

This table compares GeneNews and Akumin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GeneNewsN/AN/AN/A
AkuminN/AN/AN/A

Summary

Akumin beats GeneNews on 4 of the 5 factors compared between the two stocks.

LED Medical Diagnostics (CVE:LMD) and Akumin (TSE:AKU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.

Profitability

This table compares LED Medical Diagnostics and Akumin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LED Medical DiagnosticsN/AN/AN/A
AkuminN/AN/AN/A

Valuation & Earnings

This table compares LED Medical Diagnostics and Akumin's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LED Medical DiagnosticsC$14.96 million1.04C$-1,512,615.00C($0.04)-10.26
AkuminC$269.04 million1.21C$-1,396,820.00C($0.02)-233.50

Akumin has higher revenue and earnings than LED Medical Diagnostics. Akumin is trading at a lower price-to-earnings ratio than LED Medical Diagnostics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for LED Medical Diagnostics and Akumin, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LED Medical Diagnostics0000N/A
Akumin01102.50

Akumin has a consensus target price of C$4.25, indicating a potential downside of 8.99%. Given Akumin's higher possible upside, analysts plainly believe Akumin is more favorable than LED Medical Diagnostics.

Summary

Akumin beats LED Medical Diagnostics on 6 of the 7 factors compared between the two stocks.

VentriPoint Diagnostics Ltd. (VPT.V) (CVE:VPT) and Akumin (TSE:AKU) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares VentriPoint Diagnostics Ltd. (VPT.V) and Akumin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VentriPoint Diagnostics Ltd. (VPT.V)N/AN/AN/A
AkuminN/AN/AN/A

Valuation and Earnings

This table compares VentriPoint Diagnostics Ltd. (VPT.V) and Akumin's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VentriPoint Diagnostics Ltd. (VPT.V)C$37,517.001,483.81C$-4,128,201.00C($0.03)-13.48
AkuminC$269.04 million1.21C$-1,396,820.00C($0.02)-233.50

Akumin has higher revenue and earnings than VentriPoint Diagnostics Ltd. (VPT.V). Akumin is trading at a lower price-to-earnings ratio than VentriPoint Diagnostics Ltd. (VPT.V), indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for VentriPoint Diagnostics Ltd. (VPT.V) and Akumin, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VentriPoint Diagnostics Ltd. (VPT.V)0000N/A
Akumin01102.50

Akumin has a consensus target price of C$4.25, suggesting a potential downside of 8.99%. Given Akumin's higher possible upside, analysts clearly believe Akumin is more favorable than VentriPoint Diagnostics Ltd. (VPT.V).

Summary

Akumin beats VentriPoint Diagnostics Ltd. (VPT.V) on 5 of the 7 factors compared between the two stocks.


Akumin Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
LXG
LexaGene
0.5$1.10flatC$83.27 millionN/A-11.58News Coverage
SQD
SQI Diagnostics Inc. (SQD.V)
0.9$0.40flatC$52.59 millionC$1.02 million-12.34Gap Up
SVA
Sernova Corp. (SVA.V)
0.5$1.43flatC$31.35 millionN/A-52.96Gap Down
GEN
GeneNews
0.5N/AN/AC$24.65 millionC$234,592.00-2.21
LMD
LED Medical Diagnostics
0.4$0.40flatC$15.51 millionC$14.96 million-10.26Gap Down
VPT
VentriPoint Diagnostics Ltd. (VPT.V)
0.6$0.45flatC$5.58 millionC$37,517.00-13.48Gap Down
IDL
Imaging Dynamics Company Ltd. (IDL.V)
0.4$0.08flatC$4.13 millionC$378,253.00-4.21Gap Up
DXD
3D Signatures
0.5$0.04flatC$2.66 millionN/A-0.91Gap Down
MBI
Med Biogene
0.5$0.05flatC$795,000.00N/A-7.50Gap Up
BUX
(BUX)
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
Gap Up
IME
12144
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
CRL
Charles River Laboratories International
0.5N/AN/A$0.00N/A0.00Gap Up
This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.